Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement

Whitley MJ, Wang JX, Chapman J, de Vries APJ, Chandran S, Glennon CM, Madariaga HM, Carroll RP, Booth J, Concepcion B, Couzi L, De Serres[...]

A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease

Brownstein AJ, Lliang L, Channick R, Kim A, Saggar R. A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease. Eur Respir[...]

Indefinite for dysplasia in Barrett’s esophagus: definitely worth your attention

Muthusamy VR. Indefinite for dysplasia in Barrett's esophagus: definitely worth your attention. Gastrointest Endosc. 2026 Jan;103(1):84-86. doi: 10.1016/j.gie.2025.06.024. PMID: 41412705.